Incanthera Limited

Ellipses Pharma Limited

Somanta Limited

Biostatus Limited

Laurence Patterson

Jason Gill

Paul Loadman

Michael Bibby

Jennifer Xavier

Rob Falconer

Robert Falconer

Jennifer Atkinson

Rachel Jane Errington

Paul Smith

Stephanie McKeown

Stefan Ogrodzinski

Paul Henry Teesdale-Spittle

Mike Bibby

Klaus Pors

Stephanie Mckeown

Robert Andrew Falconer

The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.

Methods of treating cancer using compounds containing a vascular disrupting agent

The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.

Compounds containing a vascular disrupting agent

The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a matrix metalloproteinase (MMP) proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.

Compounds

Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which Rto Rare each selected from the group consisting of H, Calkyl, X, &#x2014;NHRN (R)in which Ris a Calkanediyl and each Ris H or optionally substituted Calkyl, and a group of formula (II) in which at least one of R, Rand Ris selected from X, and Xsubstituted Calkyl and any others are H or Calkyl; Ris selected from H, Calkyl, Xand Xsubstituted Calkyl; m is 0 or 1; n is 1 or 2; Xis a halogen atom, a hydroxyl group, a Calkoxyl group, an aryloxy group or an acyloxy group; and Xis a halogen atom, a hydroxyl group, a Calkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of Rto Ris a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives. The amine compounds are cytotoxic and may be used as alkylating agents having topoisomerase II inhibiting activities in cancer therapy. 

Anthraquinone compounds as anti cancer compounds

Growing community of inventors

West Yorkshire, United Kingdom

Laurence Patterson